Table 3.
KEGG Pathway enrichment analyses were performed on dysregulated miRNAs identified in Cron et al. (A) and Sengupta et al. (B) using miRNet (https://www.mirnet.ca/miRNet/home.xhtml).
| Pathway | Hits | P-value |
|---|---|---|
| A | ||
| Pathways in cancer | 90 | 6.49E-29 |
| Prostate cancer | 35 | 2.74E-15 |
| Focal adhesion | 53 | 1.75E-14 |
| Pancreatic cancer | 30 | 2.21E-14 |
| Glioma | 28 | 2.38E-13 |
| Chronic myeloid leukemia | 29 | 8.4E-13 |
| Colorectal cancer | 23 | 5.21E-12 |
| Small cell lung cancer | 29 | 1.04E-11 |
| Regulation of actin cytoskeleton | 44 | 8.61E-11 |
| Neurotrophin signaling pathway | 35 | 1E-10 |
| Melanoma | 25 | 2.36E-10 |
| Acute myeloid leukemia | 22 | 1.26E-09 |
| Bacterial invasion of epithelial cells | 21 | 6.06E-09 |
| Non-small cell lung cancer | 20 | 8.82E-09 |
| Chemokine signaling pathway | 41 | 1.12E-08 |
| Adherens junction | 23 | 1.49E-08 |
| Renal cell carcinoma | 21 | 2.05E-08 |
| Toxoplasmosis | 26 | 5.40E-08 |
| ErbB signaling pathway | 25 | 5.50E-08 |
| Endometrial cancer | 17 | 1.16E-07 |
| Jak-STAT signaling pathway | 26 | 1.96E-07 |
| HTLV-I infection | 39 | 4.22E-07 |
| T cell receptor signaling pathway | 25 | 6.37E-07 |
| Insulin signaling pathway | 30 | 1.22E-06 |
| Chagas disease (American trypanosomiasis) | 23 | 1.55E-06 |
| p53 signaling pathway | 19 | 4.85E-06 |
| Cholinergic synapse | 23 | 5.12E-06 |
| B cell receptor signaling pathway | 20 | 5.17E-06 |
| Bladder cancer | 12 | 5.17E-06 |
| mTOR signaling pathway | 15 | 5.53E-06 |
| Epstein-Barr virus infection | 22 | 8.07E-06 |
| Hepatitis C | 23 | 1.14E-05 |
| Leukocyte transendothelial migration | 24 | 1.27E-05 |
| MAPK signaling pathway | 43 | 1.39E-05 |
| Apoptosis | 20 | 2.34E-05 |
| Progesterone-mediated oocyte maturation | 19 | 5.02E-05 |
| Type II diabetes mellitus | 14 | 6.24E-05 |
| Fc epsilon RI signaling pathway | 18 | 7.05E-05 |
| Fc gamma R-mediated phagocytosis | 21 | 7.34E-05 |
| Melanogenesis | 21 | 1.38E-04 |
| Thyroid cancer | 10 | 1.50E-04 |
| VEGF signaling pathway | 17 | 2.95E-04 |
| TGF-beta signaling pathway | 18 | 3.21E-04 |
| Hypertrophic cardiomyopathy (HCM) | 9 | 3.30E-04 |
| Axon guidance | 22 | 4.47E-04 |
| Tight junction | 22 | 4.47E-04 |
| Wnt signaling pathway | 25 | 4.97E-04 |
| Tuberculosis | 28 | 7.46E-04 |
| Aldosterone-regulated sodium reabsorption | 10 | 8.17E-04 |
| Carbohydrate digestion and absorption | 7 | 1.11E-03 |
| Alcoholism | 26 | 1.86E-03 |
| Cell cycle | 21 | 2.22E-03 |
| Dopaminergic synapse | 21 | 2.22E-03 |
| Measles | 18 | 3.27E-03 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 5 | 5.68E-03 |
| ECM-receptor interaction | 15 | 7.47E-03 |
| Osteoclast differentiation | 19 | 7.74E-03 |
| GnRH signaling pathway | 16 | 8.65E-03 |
| Herpes simplex infection | 17 | 8.84E-03 |
| Dilated cardiomyopathy | 14 | 9.31E-03 |
| Adipocytokine signaling pathway | 12 | 1.10E-02 |
| Toll-like receptor signaling pathway | 16 | 1.13E-02 |
| Salmonella infection | 13 | 1.18E-02 |
| Influenza A | 16 | 2.90E-02 |
| Basal cell carcinoma | 9 | 3.19E-02 |
| Cardiac muscle contraction | 4 | 3.59E-02 |
| Dorso-ventral axis formation | 4 | 3.59E-02 |
| NOD-like receptor signaling pathway | 9 | 4.00E-02 |
| Cytokine-cytokine receptor interaction | 30 | 4.15E-02 |
| Viral myocarditis | 6 | 4.15E-02 |
| B | ||
| Pathways in cancer | 87 | 3.17E-26 |
| Chronic myeloid leukemia | 33 | 4.40E-16 |
| HTLV-I infection | 55 | 9.17E-16 |
| Prostate cancer | 34 | 1.64E-14 |
| Colorectal cancer | 25 | 6.48E-14 |
| Pancreatic cancer | 29 | 1.88E-13 |
| Focal adhesion | 51 | 2.62E-13 |
| Melanoma | 27 | 6.84E-12 |
| Glioma | 26 | 1.40E-11 |
| Non-small cell lung cancer | 22 | 2.12E-10 |
| Endometrial cancer | 20 | 3.46E-10 |
| Bladder cancer | 16 | 8.40E-10 |
| Small cell lung cancer | 26 | 2.43E-09 |
| Cell cycle | 33 | 2.95E-09 |
| Thyroid cancer | 14 | 6.34E-08 |
| Osteoclast differentiation | 30 | 7.38E-08 |
| ErbB signaling pathway | 25 | 7.70E-08 |
| Renal cell carcinoma | 20 | 1.53E-07 |
| Toll-like receptor signaling pathway | 26 | 1.62E-07 |
| Regulation of actin cytoskeleton | 38 | 1.62E-07 |
| Toxoplasmosis | 25 | 2.78E-07 |
| Acute myeloid leukemia | 19 | 2.92E-07 |
| Adherens junction | 21 | 4.24E-07 |
| Chagas disease (American trypanosomiasis) | 24 | 4.36E-07 |
| p53 signaling pathway | 20 | 1.10E-06 |
| mTOR signaling pathway | 16 | 1.10E-06 |
| Bacterial invasion of epithelial cells | 18 | 1.10E-06 |
| MAPK signaling pathway | 46 | 1.25E-06 |
| Leukocyte transendothelial migration | 26 | 1.25E-06 |
| VEGF signaling pathway | 21 | 1.57E-06 |
| Epstein-Barr virus infection | 22 | 9.71E-06 |
| Neurotrophin signaling pathway | 26 | 1.63E-05 |
| B cell receptor signaling pathway | 19 | 2.30E-05 |
| Axon guidance | 25 | 2.31E-05 |
| TGF-beta signaling pathway | 20 | 3.37E-05 |
| Fc epsilon RI signaling pathway | 18 | 8.65E-05 |
| Apoptosis | 19 | 1.01E-04 |
| T cell receptor signaling pathway | 21 | 1.05E-04 |
| Chemokine signaling pathway | 31 | 3.46E-04 |
| Influenza A | 21 | 3.99E-04 |
| Hepatitis C | 20 | 4.38E-04 |
| Wnt signaling pathway | 25 | 6.63E-04 |
| Measles | 19 | 1.66E-03 |
| Insulin signaling pathway | 23 | 1.95E-03 |
| Salmonella infection | 15 | 1.95E-03 |
| Jak-STAT signaling pathway | 18 | 3.02E-03 |
| Type II diabetes mellitus | 11 | 4.79E-03 |
| Progesterone-mediated oocyte maturation | 15 | 5.83E-03 |
| Epithelial cell signaling in Helicobacter pylori infection | 9 | 8.37E-03 |
| Carbohydrate digestion and absorption | 6 | 8.44E-03 |
| Natural killer cell mediated cytotoxicity | 21 | 1.08E-02 |
| GnRH signaling pathway | 16 | 1.08E-02 |
| Amyotrophic lateral sclerosis (ALS) | 9 | 1.14E-02 |
| Fc gamma R-mediated phagocytosis | 16 | 1.44E-02 |
| Aldosterone-regulated sodium reabsorption | 8 | 1.65E-02 |
| ECM-receptor interaction | 14 | 2.21E-02 |
| Cholinergic synapse | 15 | 2.73E-02 |
| Long-term potentiation | 12 | 3.04E-02 |
| Amoebiasis | 9 | 3.26E-02 |
| Tight junction | 17 | 3.95E-02 |
| Dorso-ventral axis formation | 4 | 3.96E-02 |
| Legionellosis | 8 | 3.96E-02 |
| Hypertrophic cardiomyopathy (HCM) | 6 | 3.96E-02 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 4 | 3.96E-02 |
| One carbon pool by folate | 5 | 4.62E-02 |
| Viral myocarditis | 6 | 4.62E-02 |
Pathways of interest are highlighted: cancer pathways (gray), pathogen infection pathways (blue), Toll-Like Receptor signaling pathway (green) and chemokine signaling pathway (yellow).